Business Insider

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, ...
Benzinga.com

EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market

Scienture Holdings, Inc. (NASDAQ:SCNX) on Tuesday announced that it has formalized a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the ...
Santé log

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 ...
MarketWatch

(PMZN) SCIENTURE'S Arbli(TM) Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

The MarketWatch News Department was not involved in the creation of this content. Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to ...
Nasdaq

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension “The commercial launch of Arbli™ ...